Back to Search
Start Over
Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.
- Source :
-
Investigational new drugs [Invest New Drugs] 1988 Sep; Vol. 6 (3), pp. 217-8. - Publication Year :
- 1988
-
Abstract
- Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderate.
- Subjects :
- Adult
Aged
Drug Evaluation
Female
Humans
Male
Middle Aged
Ribavirin adverse effects
Ribavirin analogs & derivatives
Antineoplastic Agents therapeutic use
Carcinoma, Bronchogenic drug therapy
Carcinoma, Small Cell drug therapy
Lung Neoplasms drug therapy
Ribavirin therapeutic use
Ribonucleosides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0167-6997
- Volume :
- 6
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Investigational new drugs
- Publication Type :
- Academic Journal
- Accession number :
- 2847992
- Full Text :
- https://doi.org/10.1007/BF00175401